NASDAQ:CNTB
Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd's revenue fell 99.8% in fiscal 2025 to $64,000 while operating margin fell to −90740.6%. Free cash flow was −$51.6M, −80687.5% of revenue, and the diluted share count rose 0.8%.Summary generated from Connect Biopharma Holdings Ltd's SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$64,000
Revenue growth−99.8%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−90740.6%
Net margin−86687.5%
ROICn/a
Return on equity−82.7%
Debt / equityn/a
Free cash flow−$51.6M
FCF margin−80687.5%
Share count change+0.8%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 26 | 0 |
| Operating income | −69 | −22 | −58 |
| Net income | −62 | −16 | −55 |
| Free cash flow | −48 | −24 | −52 |
Recent filings
- 4Insider transaction report
Oct 1, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KRegulation FD disclosure
Sep 30, 2026 - 8-KRegulation FD disclosure
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 12, 2026